Our in vivo findings provide evidence that the glutathione metabolism pathway contributes to ESCC progression via inhibition of the NF-kB signaling pathway and provides a groundwork for further development of a glutathione metabolism inhibitor to treat ESCC
Proteins of interest were probed with primary antibodies against GS (Millipore, MAB302), YAP (Cell Signaling Technology, D8H1X), phospho-YAP (Ser127, Cell Signaling Technology, D9W2I), -tubulin (Sigma-Aldrich, T5168), GAPDH (Santa Cruz Biotechnology, SC365062), Lamin B1 (Santa Cruz Biotechnology, SC377000), LATS1 (Cell Signaling Technology, C66B5), phospho-LATS1 (Ser909, Cell Signaling Technology, 9157), MST1 (Cell Signaling Technology, 3682), phospho-MST1/2 (Cell Signaling Technology, E7U1D), then probed with horseradish peroxidaseconjugated secondary antibodies (GE Healthcare) and visualized by ECL (SuperSignal West Dura Extended Duration Substrate, Thermo Fisher Scientific)
Multiple research results indicate that RGC ferroptosis is involved in the process of retinal damage triggered by I/R (Dvoriantchikova et al., 2022
Disclosures: Henriette Kreimeyer: Nothing to Disclose, Carlos Gonzalez: Nothing to Disclose, Marcos Fondevila: Nothing to Disclose, Cynthia Hsu: Nothing to Disclose, Phillipp Hartmann: Nothing to Disclose, Xinlian Zhang: Nothing to Disclose, Peter Starkel: Nothing to Disclose, Francisco Bosques: Nothing to Disclose, Elizabeth Verna: Nothing to Disclose, Juan Abraldes: Gilead: Grant/Research Support, 89bio: Consultant, Boston Pharmaceuticals: Consultant, Novo Nordisk: Consultant, Boehringer Ingelheim: Consultant, Astra Zeneca: Consultant, Agomab: Consultant, Terumo: Speaking and Teaching, Cook: Grant/Research Support, Robert Brown: Gilead: Consultant, Intercept: Consultant, Abbvie: Consultant, Madrigal: Consultant, GSK: Consultant, eGenesis: Consultant, mirum: Consultant, Victor Vargas: Ipsen: Advisor, Orphalan: Speaking and Teaching, Jose Altamirano: Nothing to Disclose, Juan Caballeria: Nothing to Disclose, Debbie Shawcross: EnteroBiotix: Consultant, MRM Health: Advisor, Satellite Bio: Consultant, Norgine: Grant/Research Support, Apollo Therapeutics: Consultant, Genfit: Advisor, Alexandre LOUVET: Glaxo-Smith-Kline: Consultant, AbbVie: Speaking and Teaching, Gilead: Speaking and Teaching, Ipsen: Consultant, Astra-Zeneca: Speaking and Teaching, Michael Lucey: Nothing to Disclose, Philippe Mathurin: Nothing to Disclose, Guadalupe Garcia-Tsao: Nothing to Disclose, Ramon Bataller: Nothing to Disclose, Susan Mayo: Nothing to Disclose, David Gonzalez: Nothing to Disclose, Bernd Schnabl: Mabwell Therapeutics: Consultant, Ambys Medicines: Consultant, Surrozen: Consultant, Nterica Bio: Stock privately held company, Axial Biotherapeutics: Grant/Research Support, Prodigy Biotech: Grant/Research Support, CymaBay Therapeutics: Grant/Research Support, Intercept Pharmaceuticals: Grant/Research Support, ChromoLogic: Grant/Research Support 2069 NADH-REDUCTIVE STRESS LINKS THE ANTIOXIDANT CULLIN3-RING E3 LIGASE-NRF2 AXIS TO REGULATION OF HEPATIC STEATOSIS AND INSULIN SENSITIVITY Lijie Gu 1 Yanhong Du 1 Jianglei Chen 1 Mohammad Nazmul Hasan 1 Tiangang Li 1 , 1 University of Oklahoma Health Sciences Center Background Obesity and insulin resistance are major pathogenic drivers of metabolic dysfunction-associated steatotic liver disease (MASLD)
A human serum albumin solution (Cormay, Poland) was used as a standard
Front Immunol (2018) 9:973
